Psychiatry and Clinical Psychopharmacology
Case Report

Neuroleptic malignant syndrome during the use of extended release quetiapine: a case report

1.

Department of Psychiatry, Elazig Training and Research Hospital, Elazig - Turkey

2.

Department of Psychiatry, Istanbul School of Medicine, Istanbul - Turkey

3.

Department of Infectious Diseases and Clinical Microbiology, Elazig Training and Research Hospital, Elazig - Turkey

4.

Department of Anaesthesia and Intensive Care, Elazig Training and Research Hospital, Elazig - Turkey

Psychiatry and Clinical Psychopharmacology 2012; 22: 352-354
DOI: 10.5455/bcp.20120731061958
Read: 636 Downloads: 403 Published: 25 February 2021

Neuroleptic malignant syndrome (NMS), is a potentially life-threatening condition which is rarely seen during antipsychotic use. Neuroleptic malignant syndrome is characterized by the imbalance of central neurotransmitters, in which a dopaminergic block is developed. Hyperthermia, muscular rigidity, tremor, autonomic dysfunction, an increase in serum creatine phosphokinase levels, leukocytosis, and altered mental status can be seen in this syndrome. In this study, we present a 50 year old woman with NMS that occurred during the use of extended release quetiapine, who had been diagnosed with atypical psychotic disorder for 5 years.


Uzatılmış salınımlı ketiapin kullanımında nöroleptik malign sendrom: Olgu sunumu

Nöroleptik malign sendrom (NMS), antipsikotiklerin kullanımı sırasında nadir görülen, potensiyel olarak yaşamı tehdit eden bir durumdur. NMS, dopaminerjik reseptörlerde blokaj gelişmesi ve santral nörotransmitterlerde dengesizlik oluşumu ile karakterize bir sendromdur. Bu sendromda hipertermi, kas rijiditesi, tremor, otonomik disfonksiyon, serum kreatin fosfokinazda yükselme, lökositoz ve bilinç değişiklikleri görülebilir. Bu yazıda, 5 yıldır atipik psikotik bozukluk tanısıyla takip edilen 50 yaşındaki kadın hastada uzatılmış salınımlı ketiapin kullanımı sırasında ortaya çıkan NMS olgusu sunulmuştur

Files
EISSN 2475-0581